Andy is a highly experienced drug development leader with more than 20 years experience in multiple myeloma. Most recently, he served as Executive Director and Global Project Leader for Takeda Pharmaceuticals’ Oncology Therapeutic Area, focused on myeloma. His expertise encompasses strategic planning, risk assessment and mitigation, and life cycle management, all driven by a strong commitment to fostering high-performing teams.

Previously, Andy has held senior roles across biotech, pharma, Clinical Research Organisations (CROs), as well as academia. His career is distinguished by significant contributions to several life-changing therapies for patients with multiple myeloma, including the development of VELCADE® and NINLARO®.